Hammerberg Lawyers LLP has filed a Losartan-containing drugs class action suit on behalf of Canadian residents in light of Health Canada’s March 9, 2019 drug recall advisory.
Multiple lots of Losartan-containing drugs are being voluntarily recalled by Teva Canada, Apotex Inc., Pharmascience Inc., and Pro Doc Limitée because of the potential for a nitrosamine impurity, N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). NMBA is potentially a human carcinogen, which means that long-term exposure could increase the potential risk of cancer.
Please contact Hammerberg Partner, Kevin McLaren, if you think you may have been affected by the Losartan drug recall — you may be entitled to compensation. email@example.com
To read the Health Canada recall advisory, click here